Loading
Cancer Research and Treatment / Radiomics and Machine Learning in Medical Imaging / Nanoparticle-based Drug Delivery · Journal article
Journal of Pharmaceutical Research and Integrated Medical Sciences · August 17, 2026
Raises a question worth testing. It does not answer one.
This is a narrative review synthesizing concepts in AI-integrated nanomedicine for oncology across multiple cancer types. It identifies emerging technologies and unmet challenges in translation but presents no original empirical data, clinical trials, or quantified outcomes to support clinical practice or validate therapeutic approaches.
Journal article.
Integration of machine learning, deep learning, and computational methods with nano delivery systems has improved carrier design, formulation optimization, multiscale targeting, and therapy monitoring AI applications highlighted include tumor identification, patient stratification, theranostics, and specific focus on brain, liver, breast, and kidney cancers Emerging technologies discussed: digital twins, federated learning, explainable AI, large language models, and intelligent nanorobotics are proposed to accelerate clinical translation
Safety was not reported in the material analysed. Check the source before drawing any conclusion about harm.
This review describes conceptual and technological landscape rather than providing evidence to guide clinical decision-making. Readers should recognize it as an overview of potential future directions, not a summary of validated clinical applications.
A narrative review of AI applications in nanomedicine oncology that raises conceptual possibilities and identifies research directions rather than reporting empirical results or clinical outcomes.
This review describes conceptual and technological landscape rather than providing evidence to guide clinical decision-making. Readers should recognize it as an overview of potential future directions, not a summary of validated clinical applications.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
What is missing. This record has no reported figures. That is a gap in the analysis, not a judgement about the study.
The emergence of artificial intelligence (AI) has proved to be an important development in the field of translational nanomedicine, as it has made possible intelligent and personalized applications for precision oncology. The integration of machine learning (ML), deep learning, nanoinformatics, predictive modeling, and computational methods with nano delivery systems has improved carrier design, formulation optimization, multiscale targeting, and therapy monitoring using AI. This article discusses some of the latest developments in the area of AI-assisted translational nanomedicine. It also highlights the use of AI in tumor identification, patient stratification, theranostics, and the application of AI in brain, liver, breast, and kidney cancers. Moreover, cutting-edge developments in digital twins, federated learning, explainable AI, large language models, and intelligent nanorobotics are described for their capacity to speed up clinical translation. While much has been accomplished, there are issues regarding data standardization, clinical validation, scalable manufacturing, regulatory clearance, and algorithm transparency that need to be addressed.
Taken from the source record, never inferred. Follow any of these and new work involving them reaches your briefing.